Vocal-cord vs. Complete Laryngeal Radiation Therapy for Early Glottic Cancer

Official Title

A Randomized Study of Vocal-cord Only vs. Complete Laryngeal Radiation Therapy for Early Glottic Cancer


This is a multicentre, randomized Bayesian Phase II trial for patients with early stage (T1N0) glottic squamous cell carcinoma treated with radical radiation therapy. The primary objective is to assess the non-inferiority of local control achieved with vocal-cord only radiation therapy (VC-RT) compared to complete larynx radiation therapy (CL-RT) in T1N0 glottic laryngeal squamous cell cancer, measured at 2-years after treatment. Secondary outcomes include overall survival, as well as voice impairment, dysphagia and quality of life, measured respectively by the voice handicap index -10 (VHI-10), the MD Anderson Dysphagia Inventory (MDADI) and the MD Anderson Symptom Inventory- Head and Neck module (MDASI-HN). Patients will be randomized in a 1:3 ratio to CL-RT (39 patients) and VC-RT (116 patients) arms. There will be stratification by tumour stage (T1a/T1b) and by institution. An interim analysis is planned after the first 55 patients enrolled on the experimental arm have a 6-month follow-up.

Trial Description

Primary Outcome:

  • Local control
Secondary Outcome:
  • Voice Handicap Index-10 score
  • MD Anderson Dysphagia Inventory score
  • MD Anderson Symptom Inventory-Head & Neck score
  • Consensus Auditory-Perceptual Evaluation of Voice (CAPE-V)
  • Rates of acute toxicity as per CTCAE v5.0
  • Rates of chronic toxicity as per CTCAE v5.0
  • Rates of new hypothyroidism
  • Rates of cerebrovascular event (transient ischemic attack or stroke)
  • Overall survival
  • Time to recurrence

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society